

BIOCON GROUP

FINANCIALS

H1 FY 2007 vs H1 FY 2006

FACT SHEET

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT
Rs Crores

Particulars	H1 FY 2007	H1 FY 2006	Variance H1 FY 07 vs H1 FY 06
<u>INCOME</u>			
Sales-Biopharmaceuticals	344	290	18%
Sales- Enzymes	48	42	14%
Contract research and licensing fees	69	42	66%
Total Sales	461	374	23%
Other income	2	3	
Total Income / Revenues	463	377	23%
<u>EXPENDITURE</u>			
Material & Power Costs	252	208	21%
Staff costs	41	31	31%
Other expenses	48	26	82%
Manufacturing, staff & other exps	341	265	29%
PBDIT /EBIDTA	122	112	9%
Interest and finance charges	4	0	
PBDT	118	112	6%
Depreciation	29	15	
PBT	89	97	-8%
Taxes	6	16	
PROFIT FOR THE PERIOD	83	81	2%
Add/(less): Minority interest	1	1	
PAT	84	82	3%
EPS on issued capital (Rs)	8.4	8.2	3%

Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		<i>(Rs. crores)</i>
Particulars	As at 30-Sep-06	As at 31-Mar-06
<u>SOURCES OF FUNDS</u>		
Share Capital	50	50
Reserves & Surplus	925	838
Total Shareholder's Funds	975	888
Minority interest	2	3
Deferred Tax Liability	31	30
Secured Loans	118	68
Unsecured Loans	43	37
Total Loan Funds	161	105
Total	1,169	1,026
<u>APPLICATION OF FUNDS</u>		
Fixed Assets (Net)	857	827
Intangible Assets	52	-
Investments	80	100
Inventories	149	110
Sundry debtors	256	224
Cash and bank balances	7	2
Loans and advances	29	24
Total Current Assets, Loans & Advances	441	360
Less: Current liabilities and provisions	261	261
Net Current assets	180	99
Total	1,169	1,026

BIOCON LIMITED (CONSOLIDATED)		
STATEMENT OF CASH FLOWS		<i>(Rs. crores)</i>
Particulars	Half Year ended September 30, 2006	Full Year ended March 31, 2006
<u>I. Cash Flow from Operating Activities</u>		
Net profit before tax	89	203
Less/Add: non-cash items/ items required separately		
Depreciation	29	30
Others	4	(2)
Changes in working capital and other provisions	(33)	(127)
Cash generated from operations	89	104
Tax paid (net of refunds)	(4)	(23)
Net Cash provided by operating activities	85	81
<u>II. Cash Flow from Investing Activities</u>		
Fixed Assets	(95)	(229)
Change in minority Interest	-	0
Interest / dividend received	2	5
Investments	(13)	135
Net cash used for investing activities	(106)	(89)
<u>III. Cash Flows from Financing Activities</u>		
Borrowings and other financing activities	23	5
Net Cash provided/(used) for financing activities	23	5
<u>IV. Net Change in Cash and Cash Equivalents (I+II+III)</u>	2	(3)
<u>V. Cash & Cash Eq. at the beginning of the year</u>	2	3
<u>VI CASH AND CASH EQUIVALENTS OF THE ESOP TRUST ACQUIRED DURING THE YEAR</u>	3	2
<u>VII. Cash and Cash Eq. at the end of the year (IV+V+VI)</u>	7	2